Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 15/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013521 | 0.91 | RAB9A (0.36) | MAPK1HRH3F2RL3KDM4E | |
| SCHEMBL3008408 | 0.90 | F2RL3 (0.36) | ALDH1A1HRH3F2RL3 | |
| SCHEMBL3000434 | 0.87 | RAB9A (0.38) | ALDH1A1HRH3F2RL3 | |
| SCHEMBL3019281 | 0.87 | HRH3 (0.35) | ALDH1A1GAAMAPK1HRH3 | |
| SCHEMBL3004088 | 0.87 | ALDH1A1 (0.35) | ALDH1A1HRH3 | |
| SCHEMBL3011245 | 0.86 | HRH3 (0.35) | HRH3F2RL3KDM4E | |
| SCHEMBL3019251 | 0.86 | ALDH1A1 (0.38) | ALDH1A1GAAMAPK1F2RL3KDM4E | |
| SCHEMBL3019927 | 0.86 | MAPK1 (0.53) | ALDH1A1GAAMAPK1KDM4E | |
| SCHEMBL3004144 | 0.86 | ALDH1A1 (0.39) | ALDH1A1GAAMAPK1HRH3F2RL3 | |
| SCHEMBL3009855 | 0.86 | HRH3 (0.34) | ALDH1A1MAPK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | ALDH1A1 3510/4885GAA 110/4885MAPK1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.